Improvement of cardiovascular risk factors and cosmetic side effects in kidney transplant recipients after conversion to tacrolimus

Biomedical Papers

Volumn 153, Issue 1, 2009, Pages 67-74

  Zadrazil, Josef ^a   Horak, Pavel ^a   Zahalkova, Jana ^a   Strebl, Pavel ^a   Horcicka, Vladko ^a   Krejci, Karel ^a   Bachleda, Petr ^a   Dedochovaivo, Jarmila ^b   Valkovsky, Ivo ^b  

^a UNIVERSITY HOSPITAL OLOMOUC   (Czech Republic)

^b Teaching Hospital   (Czech Republic)

Author keywords

Cardiovascular mortality; Cyclosporine; Hyperlipidemia; Hypertension; Renal transplantation; Side eff ects; Tacrolimus

Indexed keywords

CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; TACROLIMUS;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CHEMICALLY INDUCED DISORDER; FEMALE; GINGIVA HYPERPLASIA; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; HYPERTRICHOSIS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; RISK FACTOR;

ADULT; CARDIOVASCULAR DISEASES; CYCLOSPORINE; FEMALE; GINGIVAL HYPERPLASIA; HUMANS; HYPERLIPIDEMIAS; HYPERTENSION; HYPERTRICHOSIS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; RISK FACTORS; TACROLIMUS;

EID: 70149109796     PISSN: 12138118     EISSN: 12138118     Source Type: Journal    
DOI: 10.5507/bp.2009.012     Document Type: Article

References (30)

1. Almawi WY, Melemedjian O. Clinical and mechanistic differences between FK 506 (tacrolimus) and cyclosporin A. Nephrol Dial Transplant 2000; 15: 1946-1978.
2. Tang IY, Meier-Kriesche HU, Kaplan B. Immunosuppressive strategies to improve outcomes of kidney transplantation. Semin Nephrol 2007; 4: 377-392.
3. Kahan BD. Ciclosporin. N Engl J Med 1989; 321: 1725-1738.
4. Ligtenberg G, Hene RJ, Blankestijn PJ, Koomans HA. Cardiovascular risk factors in renal transplant patients: cyclosporin A versus tacrolimus. J Am Soc Nephrol 2001; 12: 368-373.
5. Roodnat JI, Mulder PG, Zietse R, Rischen-Vos J, vanRiemsdijk IC, IJzermans JN et al. Cholesterol as an independent predictor of outcome after renal transplantation. Transplantation 2000; 69: 1704-1710.
6. Castelló IB. Hyperlipidemia: A risk factor for chronic allograft dysfunction. Kidney Int 2002; 61:73-77.
7. Busque S, Demers P, St-Louis G, Boily JG, Tousignant J, Lemieux F et al. Conversion from Neoral (cyclosporine) to tacrolimus of kidney transplant recipients for gingival hyperplasia or hypertrichosis. Transplant Proc 1998; 30:1247-1248.
8. Friemann S, Feuring E, Padberg W, Ernst W. Improvement of nephrotoxicity, hypertension, and lipid metabolism after conversion of kidney transplant recipients from cyclosporine to tacrolimus. Transplatn Proc 1998; 30:1240-1242.
9. Copley JB, Staffeld C, Lindberg J, Hansen A, Bailey C, Anand R et al. Cyclosporin to tacrolimus: effect on hypertension and lipid profiles in renal allografts. Transplant Proc 1998; 30:1254-1256.
10. Fernando ON, Sweny P, Varghese Z. Elective conversion of patients from cyclosporine to tacrolimus for hypertrichosis. Transplant Proc 1998; 30:1243-1244.
11. Matsuda S, Koyasu S. Mechanism of action of cyclosporine. Immunopharmacology 2000; 47: 119-125.
12. Margreiter R for the European Tacrolimus vs Ciclosporin Microemulsion Renal Transplant Study Group. Efficacy and safety of tacrolimus compared with ciclosporin microemulsion in renal transplantation: A randomised multicentre study. Lancet 2002; 395: 741-746.
13. Vincenti F, Jensik SC, Filo RS, Miller J, Pirsch J. A long-term comparison of tacrolimus (FK-506) and cyclosporine in kidney transplantation: Evidence for improved allograft survival at five years. Transplantation 2002; 73:775-782.
14. Klein IHHT, Abrahams A, van Ede T, Hené RJ, Koomans HA, Ligtenberg G. Different effects of tacrolimus and cyclosporine on renal hemodynamics and blood pressure in healthy subjects. Transplantation 2002; 73: 732-736.
15. Jiang H, Wynn C, Pan F, Ebbs A, Erickson LM, Kobayashi M. Tacrolimus and cyclosporine differ in their capacity to overcome ongoing allograft rejection as a result of their differential abilities to inhibit interleukin-10 production. Transplantation 2002; 73: 1808-1817.
16. Gaston RS. Maintenance Immunosuppression in the Renal Transplant Recipient: An Overview. Am J Kidney Dis 2001; 38 (Suppl 6): 25-35.
17. Chae HJ, Ha MS, Yun DH, Pae HO, Chung HT, Chae SW et al. Mechanism of Cyclosporine-induced overgrowth in Gingiva. J Dent Res 2006; 85: 515-519.
18. Radermacher J, Meiners M, Bramlage C, Kliem V, Behrend M, Schlitt HJ et al. Pronounced renal vasoconstriction and systemic hypertension in renal transplant patients treated with cyclosporine A versus FK 506. Transplant Int 1998;11: 3-10.
19. Kasiske BL, Snyder JJ, Gilbertson D, Matas AJ. Diabetes mellitus after kidney transplantation in the United States. Am J Transplant 2003; 3: 178-185.
20. Krämer BK, Zülke C, Kammerl MC, Schmidt C, Hengstenberg C, Fischereder M et al. European Tacrolimus vs Cyclosporine Microemulsion Renal Transplantation Study Group: Cardiovascular risk factor and estimated risk for CAD in a randomized trial comparing calcineurin inhibitors in renal transplantation. Am J Transplant 2003; 8: 982-987.
21. Krämer BK, Montagnino G, Del Castillo D, Margreiter R, Sperschneider H, Olbricht CJ et al., European Tacrolimus vs Cyclosporin Microemulsion Renal Transplantation Study Group: Efficacy and safety of tacrolimus compared with cyclosporin A microemulsion in renal transplantation: 2 year follow-up results. Nephrol Dial Transplant 2005; 20: 968-973.
22. Margreiter R, Pohanka E, Sparacino V, Sperschneider H, Kunzendorf U, Huber W et al., the European Switch to Tacrolimus Study Group: Open prospective multicenter study of conversion to tacrolimus therapy in renal transplant patients experiencing ciclosporin-related side-effects. Transplant Int 2005; 18:816-823.
23. Artz MA, Boots JM, Ligtenberg G, Roodnat JI, Christiaans MH, Vos PF et al. Improved cardiovascular risk profile and renal func- tion in renal transplant patients after randomized conversion from cyclosporine to tacrolimus. J Am Soc Nephrol 2003; 14:1880-1888.
24. Artz MA, Boots JM, Ligtenberg G, Roodnat JI, Christiaans MH, Vos PF et al. Conversion from Cyclosporine to Tacrolimus Improves Quality of-Life Indices, Renal Graft Function and Cardiovascular Risk Profile. Am J Transplant 2004; 4: 937-945.
25. Marcén R, Chahin J, Alarcón A, Bravo J. Conversion from cyclosporine microemulsion to tacrolimus in stable kidney transplant patients with hypercholesterolemia is related to an improvement in cardiovascular risk profile: a prospective study. Transplant Proc 2006; 38: 2427-2430.
26. Baid-Agrawal S, Delmonico FL, Tolkoff-Rubin NE, Farrell M, Williams WW, Shih A et al. Cardiovascular risk profile after con- version from cyclosporine A to tacrolimus in stable renal transplant recipients. Transplantation 2004; 77: 1199-1202.
27. Chamienia A, Biedunkiewicz B, Król E, Debska-Slizień A, Rutkowski B. One-year observation of kidney allograft recipients converted from cyclosporine microemulsion to tacrolimus. Transplant Proc 2006; 38:81-85.
28. Vescovi P, Meleti M, Manfredi M, Bonanini M. Pathogenesis of cyclosporine induced gingival overgrowth. Minerva Stomatol 2003; 52: 219-229.
29. Thorp M, DeMattos A, Bennett W, Barry J, Norman D. The effect of conversion from cyclosporine to tacrolimus on gingival hyperplasia, hirsutism and cholesterol. Transplantation 2000; 69: 1218-1220.
30. Kohnle M, Lütkes P, Zimmermann U, Philipp T, Heemann U. Conversion from cyclosporine to tacrolimus in renal transplant recipients with gum hyperplasia. Transplant Proc 1999; 31: 44S-45S.